Gamida Cell (GMDA) & Its Competitors Head-To-Head Analysis

Share on StockTwits

Gamida Cell (NASDAQ: GMDA) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Gamida Cell to similar businesses based on the strength of its earnings, risk, institutional ownership, analyst recommendations, profitability, dividends and valuation.

Valuation & Earnings

This table compares Gamida Cell and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Gamida Cell N/A -$52.93 million -1.11
Gamida Cell Competitors $934.76 million $204.36 million -1.39

Gamida Cell’s competitors have higher revenue and earnings than Gamida Cell. Gamida Cell is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Gamida Cell and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gamida Cell N/A N/A N/A
Gamida Cell Competitors -5,041.13% -62.99% -26.24%

Insider & Institutional Ownership

1.7% of Gamida Cell shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Gamida Cell and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gamida Cell 0 0 5 0 3.00
Gamida Cell Competitors 809 2701 5970 252 2.58

Gamida Cell currently has a consensus price target of $19.40, indicating a potential upside of 65.49%. As a group, “Biological products, except diagnostic” companies have a potential upside of 34.41%. Given Gamida Cell’s stronger consensus rating and higher probable upside, analysts clearly believe Gamida Cell is more favorable than its competitors.

Summary

Gamida Cell beats its competitors on 7 of the 12 factors compared.

Gamida Cell Company Profile

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in a patients with high-risk blood cancers, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

eXPerience Chain  Market Cap Reaches $1.98 Million
eXPerience Chain Market Cap Reaches $1.98 Million
win.win Reaches Market Capitalization of $701,282.00
win.win Reaches Market Capitalization of $701,282.00
POPCHAIN Market Capitalization Achieves $1.37 Million
POPCHAIN Market Capitalization Achieves $1.37 Million
Business Credit Alliance Chain  Price Tops $0.0045 on Exchanges
Business Credit Alliance Chain Price Tops $0.0045 on Exchanges
Actuant Co.  Expected to Announce Quarterly Sales of $301.59 Million
Actuant Co. Expected to Announce Quarterly Sales of $301.59 Million
Analysts Expect NOW Inc  Will Post Earnings of $0.09 Per Share
Analysts Expect NOW Inc Will Post Earnings of $0.09 Per Share


 
© 2006-2019 Zolmax.